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coronary and peripheral arteries, to simulate the properties of a calcific chronic partial
occlusion (CPO) lesion for the evaluation of catheter based technologies.
Forty-one pigs were prepped sterilely for creation of the CPO. An introducer sheath
was placed in the carotid artery for vascular access. Angiograms of the left anterior
descending (LAD) coronary artery and the iliac tree were obtained. A section of artery
measuring 2.8 - 3.0mm in diameter was identified and targeted for implantation with the
plug. A cylinder of bone marrow measuring 3mm in outer diameter by 10mm in length
was obtained from the rib of a donor animal and a lumen measuring approximately
1.6mm in diameter was created. The bone plug was loaded into a 9Fr guide catheter,
tracked to the targeted location within the artery and deployed. Angiography immediately
post deployment demonstrated an average lesion lumen diameter of 1.32mm (1.08 -
2.35mm).
Twenty-nine of forty-one pigs (implanted with a total of thirty-five bone plugs)
survived to the scheduled follow-up procedure (between 4 and 14 days). Thirty of the
thirty-five surviving implanted bone plugs were patent, with follow-up angiography
demonstrating reduced blood flow through the lesion, with an average lesion lumen
diameter of 1.20mm (0 - 2.59mm).
We can reliably create a porcine coronary model simulating a calcific partial occlusion,
which can be used for the evaluation of interventional technologies and platforms used to
treat coronary and peripheral artery disease. The results of previous studies have
demonstrated successful deployment of a chronic total occlusion (CTO) version of the
bone plug in the coronary and peripheral vasculature. Additionally, we have successfully
implanted larger bone marrow plugs (measuring 3.0 - 5.5mm in outer diameter) and
demonstrated the ability to reduce the calcium content of the bone marrow plug prior to
deployment, thereby decreasing the hardness of the lesion.
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Background: Carotid ultrasonography is a good non-invasive modality to evaluate
atherosclerotic changes. Intima-media thickness (IMT) is a well-established surrogate
marker of coronary atherosclerosis. But, the role of other carotid parameters for predicting
coronary artery disease (CAD) is still lack of evidence. Therefore, we evaluated the
correlation between carotid parameters and SYNTAX score (SS) representing the severity
and extent of CAD. We also investigated whether carotid parameters predict the presence
of CAD or not.
Methods: Total 663 of 1698 patients (408 men, mean age: 64.1  11.9 years) who
performed both carotid ultrasonography and coronary angiography during admission from
Sep 2011 to Aug 2012 were studied. The patients were divided into three groups: normal
or minimal CAD, 1 vessel disease (VD) and 2VD. Plaque score (PS) was defined as a
numerical summation of the presence of plaque in 4 different locations of both carotid
arteries. Maximum % diameter stenosis (DS) and area stenosis (AS) were measured at the
narrowest portion in longitudinal and short axis view.
Results: The old age, male gender, diabetes mellitus and smoking were significantly
related to the extent of CAD. All carotid parameters showed significant relationship with
the extent of CAD. Mean carotid IMT, maximum carotid IMT, PS, %AS and %DS
were weakly but significantly correlated with SS (r0.226, 0.162, 0.336, 0.361, 0.318,
respectively, all p value  0.001). After adjusted for classic risk factors, PS was the best
predictor for CAD (Odds ratio 1.576, 95% confidence interval 1.365-1.820, p0.001).
The diagnostic accuracy of PS for the detection of CAD by the area under the receiver
operating characteristics curve was 0.702 (95% confidence interval 0.661-0.743,
p0.001).
Conclusion: All carotid parameters were weakly but significantly correlated with
SYNTAX score. PS was a good predictor for coronary artery disease. Long-term
follow-up is warranted to discriminate clinical outcomes using carotid ultrasonographic
parameters.
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Objectives: Historically, women and minorities have been underrepresented in clinical
trials of drugs to treat cardiovascular disease (CVD). To accurately assess the safety and
efficacy of CVD drugs, the U.S. Food and Drug Administration (FDA) has made a
conscious effort to ensure adequate representation of women and minorities in clinical
drug trials through guidance documents and regulations. The purpose of this study is to
assess the participation of women and racial/ethnic minorities in FDA-reviewed CVD
drug trials that were included in New Drug Applications (NDAs) approved between 2010
and 2011.
Methods: The sex and race/ethnicity of subjects in all CVD drug clinical trials submitted
to FDA in support of NDAs approved between January 2010 and December 2011 were
assessed from final clinical study reports. The reports were accessed via internal FDA
databases.
Results: Four drugs (1 per NDA) indicated for hypertension (HTN), acute coronary
syndrome (ACS), non-valvular atrial fibrillation (NAF) and deep vein thrombosis/
pulmonary embolism (DVT/PE) after joint replacement surgery were approved during
the period studied. A total of 231 clinical trials classified as phase 1, 2, or 3 studies were
submitted to the NDAs. There were 107,156 subjects included in these studies.
Demographic analysis (shown in Table 1) indicated that the mean participation of women
in these trials was 41% and the majority of the trial subjects were Caucasians (79%). When
analyzed by the phase of the trials, mean female participation was 21%, 43% and 42% for
Phase 1, 2 and 3 respectively.
Table 1. Subject Demographics in CVD drug trials of NDAs approved by
FDA from 2010 to 2011.
Overall
N107156
HTN
N10558
ACS
N21127
NAF
N33662
DVT/PE
N41809
Sex
Females N (%) 44169 (41) 4643 (44) 5960 (28) 13960 (41) 19606 (47)
Males N (%) 62987 (59) 5915 (56) 15167 (72) 19702 (59) 22203 (53)
Race
Caucasian N (%) 84587 (79) 7201 (68) 18942 (90) 26291 (78) 32153 (77)
Black N (%) 2571 (2.4) 1254 (12) 462 (2.0) 228 (6.8) 627 (1.5)
Asian N (%) 9077 (8.5) 1058 (10) 1321 (6.3) 1085 (3.2) 5613 (13)
Hispanic* N (%) 1969 (1.8) 1119 (11) 66 (3.1) 0 784 (1.9)
Other** N (%) 2242 (2.1) 1027 (9.7) 343 (1.6) 159 (0.5) 713 (1.7)
Unknown^ N (%) 2111 (2.0) 0 0 466 (1.4) 1645 (3.9)
*Depending on the study, Hispanic subjects were counted either as Caucasian or a separate race/
ethnicity category. **Includes those classified as American Indian/Alaska Native, Hawaiian/Pacific
Islander, Multiracial or Other. ^Any participants whose race is listed as missing or who participated in
studieswhere therewere legal concernsaboutcollecting racedata (applied in someEuropean trials).
Conclusions: The overall inclusion of women in these CVD drug trials is comparable to
the overall female CVD population (51%) in the US. However, women are largely
underrepresented in the Phase 1 trials, during which much of the pharmacokinetics and
pharmacodynamics of new drugs are evaluated.
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